Andere Sprachen Formycon AG

Aktien

A1EWVY

DE000A1EWVY8

FYB

Biotechnologie

Markt geschlossen - Xetra Andere Börsenplätze 17:35:32 13.03.2026			% 5 Tage	Veränd. 1. Jan.
18,88 ^EUR	-2,07 %		-4,36 %	-26,25 %

13.03.	ÜBERBLICK/Anstehende Indexänderungen zum 23. März	DJ
12.03.	ÜBERBLICK/Anstehende Indexänderungen zum 23. März	DJ

Andere Sprachen

04.03.	Formycon AG publishes preliminary figures for the 2025 fiscal year
26.02.	Formycon And Lotus Expand Collaboration In Asia-Pacific Region To Pembrolizumab Biosimilar
25.02.	Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
25.02.	Formycon AG Announces Positive Clinical Data for Keytruda Biosimilar Candidate FYB206 (Pembrolizumab)
11.02.	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region
11.02.	Swiss stocks - Factors to watch on February 11
11.02.	Formycon : Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
11.02.	Formycon says Lotus Pharmaceutical to commercialize its Keytruda biosimilar in Asia-Pacific
11.02.	Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
11.02.	Formycon AG and Lotus Pharmaceutical Announce the Conclusion of an Exclusive License Agreement for Formycon's Keytruda Biosimilar Candidate FYB206
14.01.	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
13.01.	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
13.01.	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
24.12.	Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
23.12.	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar
23.12.	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco
23.12.	FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner
23.12.	Formycon AG and Bioeq AG Announce the U.S. Food and Drug Administration Approves Nufymco®?
19.12.	Formycon AG(XTRA:FYB) dropped from Germany SDAX (Total Return) Index
09.12.	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada
09.12.	Formycon AG and Zydus Lifesciences Limited Partner for Exclusive Licensing and Supply Agreement of FYB206, a Biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
09.12.	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206
09.12.	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
09.12.	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
09.12.	Formycon Ag and Zydus Lifesciences Limited Enter into Strategic Partnership for the Exclusive Licensing and Supply of Checkpoint Inhibitor Fyb206